Sienna Cancer Diagnostics Ltd. announced the initiation of a South Korean clinical study utilising the Company's novel adjunct urine cytology test, the hTERT test. The clinical study will involve a collaboration between Mirax, Sienna's exclusive Korean distribution partner, and Seoul National University Hospital (SNUH). The study, a Korean first, will provide further validation of the clinical utility of hTERT, investigating patients presenting with symptoms typically linked with bladder cancer, or being monitored for bladder cancer. The results will enable local pathologists and urologists to access data from a Korean population sample.